Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS

Amer M. Zeidan, Ju Whei Lee, Thomas Prebet, Peter Greenberg, Zhuoxin Sun, Mark Juckett, Mitchell R. Smith, Elisabeth Paietta, Janice Gabrilove, Harry P. Erba, Rhett P. Katterling, Martin S. Tallman, Steven D. Gore

Research output: Contribution to journalArticle

Abstract

Summary: Reliable clinical or molecular predictors of benefit from azacitidine therapy in patients with myelodysplastic syndromes (MDS) are not defined. Doubling of platelet count at start of second cycle of azacitidine therapy compared to baseline was associated with achieving response and survival advantage in a Dutch cohort. To validate this observation, we analysed a larger cohort of North American patients, whose data was collected in a prospective clinical trial with a longer median follow-up. We found a significant association between platelet count doubling after first cycle of azacitidine therapy and probability of achieving objective response. Among patients with MDS or oligoblastic acute myeloid leukaemia (

Original languageEnglish (US)
Pages (from-to)62-68
Number of pages7
JournalBritish Journal of Haematology
Volume167
Issue number1
DOIs
StatePublished - Oct 1 2014
Externally publishedYes

Fingerprint

Azacitidine
Myelodysplastic Syndromes
Platelet Count
Acute Myeloid Leukemia
Survival
Therapeutics
Clinical Trials

Keywords

  • Azacitidine
  • French prognostic scoring system
  • Myelodysplastic syndromes
  • Prognostic models
  • Revised international prognostic scoring system

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)

Cite this

Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS. / Zeidan, Amer M.; Lee, Ju Whei; Prebet, Thomas; Greenberg, Peter; Sun, Zhuoxin; Juckett, Mark; Smith, Mitchell R.; Paietta, Elisabeth; Gabrilove, Janice; Erba, Harry P.; Katterling, Rhett P.; Tallman, Martin S.; Gore, Steven D.

In: British Journal of Haematology, Vol. 167, No. 1, 01.10.2014, p. 62-68.

Research output: Contribution to journalArticle

Zeidan, Amer M. ; Lee, Ju Whei ; Prebet, Thomas ; Greenberg, Peter ; Sun, Zhuoxin ; Juckett, Mark ; Smith, Mitchell R. ; Paietta, Elisabeth ; Gabrilove, Janice ; Erba, Harry P. ; Katterling, Rhett P. ; Tallman, Martin S. ; Gore, Steven D. / Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS. In: British Journal of Haematology. 2014 ; Vol. 167, No. 1. pp. 62-68.
@article{e6a53879b0ae4336ae0137ff2b45b740,
title = "Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS",
abstract = "Summary: Reliable clinical or molecular predictors of benefit from azacitidine therapy in patients with myelodysplastic syndromes (MDS) are not defined. Doubling of platelet count at start of second cycle of azacitidine therapy compared to baseline was associated with achieving response and survival advantage in a Dutch cohort. To validate this observation, we analysed a larger cohort of North American patients, whose data was collected in a prospective clinical trial with a longer median follow-up. We found a significant association between platelet count doubling after first cycle of azacitidine therapy and probability of achieving objective response. Among patients with MDS or oligoblastic acute myeloid leukaemia (",
keywords = "Azacitidine, French prognostic scoring system, Myelodysplastic syndromes, Prognostic models, Revised international prognostic scoring system",
author = "Zeidan, {Amer M.} and Lee, {Ju Whei} and Thomas Prebet and Peter Greenberg and Zhuoxin Sun and Mark Juckett and Smith, {Mitchell R.} and Elisabeth Paietta and Janice Gabrilove and Erba, {Harry P.} and Katterling, {Rhett P.} and Tallman, {Martin S.} and Gore, {Steven D.}",
year = "2014",
month = "10",
day = "1",
doi = "10.1111/bjh.13008",
language = "English (US)",
volume = "167",
pages = "62--68",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS

AU - Zeidan, Amer M.

AU - Lee, Ju Whei

AU - Prebet, Thomas

AU - Greenberg, Peter

AU - Sun, Zhuoxin

AU - Juckett, Mark

AU - Smith, Mitchell R.

AU - Paietta, Elisabeth

AU - Gabrilove, Janice

AU - Erba, Harry P.

AU - Katterling, Rhett P.

AU - Tallman, Martin S.

AU - Gore, Steven D.

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Summary: Reliable clinical or molecular predictors of benefit from azacitidine therapy in patients with myelodysplastic syndromes (MDS) are not defined. Doubling of platelet count at start of second cycle of azacitidine therapy compared to baseline was associated with achieving response and survival advantage in a Dutch cohort. To validate this observation, we analysed a larger cohort of North American patients, whose data was collected in a prospective clinical trial with a longer median follow-up. We found a significant association between platelet count doubling after first cycle of azacitidine therapy and probability of achieving objective response. Among patients with MDS or oligoblastic acute myeloid leukaemia (

AB - Summary: Reliable clinical or molecular predictors of benefit from azacitidine therapy in patients with myelodysplastic syndromes (MDS) are not defined. Doubling of platelet count at start of second cycle of azacitidine therapy compared to baseline was associated with achieving response and survival advantage in a Dutch cohort. To validate this observation, we analysed a larger cohort of North American patients, whose data was collected in a prospective clinical trial with a longer median follow-up. We found a significant association between platelet count doubling after first cycle of azacitidine therapy and probability of achieving objective response. Among patients with MDS or oligoblastic acute myeloid leukaemia (

KW - Azacitidine

KW - French prognostic scoring system

KW - Myelodysplastic syndromes

KW - Prognostic models

KW - Revised international prognostic scoring system

UR - http://www.scopus.com/inward/record.url?scp=84911008768&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84911008768&partnerID=8YFLogxK

U2 - 10.1111/bjh.13008

DO - 10.1111/bjh.13008

M3 - Article

C2 - 24995683

AN - SCOPUS:84911008768

VL - 167

SP - 62

EP - 68

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 1

ER -